• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

ECI-006 is safe and well tolerated

Niel (Belgium), 19 March 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose cohort in its Phase 1b study (E011-MEL) of ECI-006 as an adjuvant therapy in metastatic melanoma patients.

Ten patients in total have been recruited for the low dose cohort (600 µg) and all patients have received at least four doses. A total of 44 doses have been administered with no adverse safety signals. Intranodal administration was associated with a 100% compliance.

eTheRNA secures EUR 24 million to develop its TriMix mRNA-based immunotherapy

Brussels (Belgium), 14 March 2016 — eTheRNA immunotherapies, a spin-off from the Brussels University 'Vrije Universiteit Brussel' (VUB), secured EUR 24 million in a Series A investment round with venture capital enabling the company to continue the development of its proprietary TriMix mRNA-based immunotherapies for melanoma, breast cancer and infectious diseases.